Corpus Intelligence IC Memo — METRO MAYAGUEZ 2026-04-26 12:34 UTC
IC Memo — METRO MAYAGUEZ
Investment Committee Memorandum | PR | 122 beds | Grade C | EBITDA uplift $3.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

METRO MAYAGUEZ

CCN 400123 | MAYAGUEZ, PR | 122 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

METRO MAYAGUEZ is a 122-bed safety-net/medicaid heavy in MAYAGUEZ, PR with $50.5M in net patient revenue and a -2.9% operating margin. The hospital serves a payer mix of 6.6% Medicare, 26.5% Medicaid, and 66.9% commercial.

Thesis: Undervalued. Our ML models identify $3.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.9% to 4.5% (+736bps).

Net Revenue HCRIS$50.5M
Current EBITDA COMPUTED$-1.5M
Operating Margin COMPUTED-2.9%
Occupancy HCRIS70.0%
Revenue / Bed COMPUTED$414K
Net-to-Gross HCRIS60.7%
Distress Probability ML52.8%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
40
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -2.9% places it above the state median. Among 40 size-comparable peers (61-244 beds), the median margin is -9.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (61-244), prioritizing same-state peers. 40 hospitals in the comp set.

HospitalStateBedsRevenueMargin
METRO MAYAGUEZ (Target)PR122$50.5M-2.9%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%
HOSPITAL DE LA CONCEPCIONPR167$91.0M-3.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$615K+122bp9mo
Clean Claim Rate88.0%96.0%$32K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.0M
Denial Rate Reduction
$1.0M
A/R Days Reduction
$615K
Clean Claim Rate
$32K
Total EBITDA Uplift$3.7M
Current EBITDA$-1.5M
+ RCM Uplift+$3.7M
Pro Forma EBITDA$2.3M
Current Margin-2.9%
Pro Forma Margin4.5%
WC Released (1x)$1.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.3M$27.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.3M$29.6M0.00x-100.0%
Bull Case9.0x11.0x$-2.0M$41.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.0M$44.2M0.00x-100.0%
Bear Case11.0x10.0x$-2.5M$9.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.5M$9.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (26.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 52.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 40 hospitals with 61-244 beds
  • Same-state prioritization (n=41)
  • Comp margins: P25=-20.8% / P50=-9.4% / P75=0.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.